Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedA service alert has been added indicating planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.8%
- Check10 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference1.0%
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check39 days agoChange DetectedThe page has been updated to reflect new results from a clinical study involving Pembrolizumab and Olaparib in advanced BRCA-mutated breast cancer, with specific metrics such as overall response rate and progression-free survival now reported. The study dates have also been revised to reflect more recent submissions and postings.SummaryDifference8%
- Check46 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.